@article {1291, title = {Lutein: A Comprehensive Review on its Chemical, Biological Activities and Therapeutic Potentials}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {November 2020}, pages = {1769-1778}, type = {Review Article}, chapter = {1769}, abstract = {

Background: Lutein is a naturally occurring carotenoid found in high amounts in flowers, grains, fruits and green vegetables with green leaves include spinach, kale and carrots. The market for lutein encompasses pharmaceutical, dietary supplement, food, animal and fish feed industries. Objective: The present review aimed to provide an updated and comprehensive analysis of lutein, including its chemistry, biological properties and therapeutic potentials. Methods: Relevant literatures were collected from several scientific databases, include Google Scholar, Pubmed and ScienceDirect between 2000 to till date. Following a detailed inclusion and exclusion screening process, the information obtained was summarized. Results: Information on the sources, chemistry and biological properties including antioxidant, anti-arthrisits, antiinflammatory, hepatoprotective, cardioprotective, anti-cataract, antidiabetic, anticancer and bone remodelling activities, as well as food industry processing for lutein were tabled. Lutein can be considered powerful antioxidants along with multifaceted molecular targets, such as NF-ҡB, PI3K/Akt, Nrf-2, HO-1 and SIRT-1 signaling pathways in various pathological conditions. Conclusion: The present review observe the chemical, pharmacological properties, in addition to the therapeutic potentials of lutein. It is hoped that the information can provide a good reference to aid in the development and utilization of lutein in phytopharmaceuticals and food industries.

}, keywords = {Antioxidant, Inflammatory cytokines, Lutein, Molecular targets, Pharmacology, Transcription factors}, doi = {10.5530/pj.2020.12.239}, author = {Nurul Iman Nurul Fuad and Mahendran Sekar and Siew Hua Gan and Pei Teng Lum and Jaishree Vaijanathappa and Subban Ravi} } @article {720, title = {Effect of Lutein on Cytochrome P450 (Isoform CYP3A4) - An in vitro Study}, journal = {Pharmacognosy Journal}, volume = {10}, year = {2018}, month = {August 2018}, pages = {1093-1095}, type = {Original Article}, chapter = {1093}, abstract = {

Background: Lutein is a carotenoids vitamin rich in many fruits and vegetables and also available in multivitamin products. It is consumed for its effect on eye disease, cancer, diabetes and other health conditions. Recently, herbal preparations are increasingly used in healthcare systems and concomitant administration of synthetic medications may cause pharmacokinetic or pharmacodynamic interactions leading to very serious medical problems. Understanding the ability of herbal extracts and preparations to modulate the metabolizing enzymes can help the health system for proper treatment of patients and thereby can avoid many adverse effects associated with it. The aim of the study was to find the effect of lutein isolated from Tagetes erecta L on cytochrome P450 isoform CYP3A4. Materials and Methods: The different concentrations of lutein (5 \– 100\μg/ml), potassium phosphate buffer, CYP450 reagent and substrate 7-Benzyloxy-4-trifluoromethylcoumarin (BFC) were added to a 96-well plate. The fluorescent intensities of the products were measured by Perkin Elmer Enspire fluorescence reader using an excitation and emission wavelength of 405 nm and 460 nm, respectively to examine the effect of lutein on Cytochrome P 450 isoform CYP3A4 and the IC50 was calculated by plotting concentrations of lutein against the corresponding percent inhibition. Results: All the tested concentrations of lutein showed potent inhibition against CYP3A4 in a dose \– dependent manner. The IC50 value was found to be 35.27\μg/ml. Conclusion: The inhibitory effect of lutein indicates the possibilities of herb-drug interaction if it is co \– administered with prescribed drugs that are normally metabolised by CYP3A4 enzyme.

}, keywords = {CYP3A4, Cytochrome P450, Inhibitory assay, Lutein, Marigold}, doi = {10.5530/pj.2018.6.185}, author = {Murthy Meenapriya and Roy Anitha and Thangavelu Lakshmi} } @article {618, title = {Inhibition of Advanced Glycation End-Product Formation by Lutein from Tagetes erecta}, journal = {Pharmacognosy Journal}, volume = {10}, year = {2018}, month = {June 2018}, pages = {734-737}, type = {Original Article}, chapter = {734}, abstract = {

Background: Advanced glycation end products(AGEs) are formed by non-enzymatic glycation of proteins that enhance vascular permeability in both micro and macro vascular structures by binding to specific macrophage receptors. AGEs affect nearly every type of cells and molecule in the body and play causative role in the vascular complication in diabetes mellitus. Materials and Method: AGE reaction solution was constituted with 10mg/ml bovine serum albumin in 50mM sodium phosphate buffer (pH 7.4) and 0.02\% sodium benzoate into 0.2M fructose and 0.2M of glucose. 2.5 ml of the reaction mixture was treated with lutein (10, 20, 40, 60, 60, 80, 100, 120, 140 \μ g/ml in methanol). Amino guanidine was used as the positive control. After incubating at 37\°C for 7 days, the fluorescence intensity of the reaction was determined at excitation and emission wavelength of 350 nm and 450 nm, respectively, using a multimode reader. The percentage activity was calculated with respect to solvent control. Result: 7 days of exposure to lutein showed a maximum inhibition of 89.27\±0.24 \% at 140\μg/ml and Amino guanidine exhibited 90\% of inhibition. The IC50 of Lutein for AGE inhibition was found to be 77.78\μg/ml and for AG, 72.66\μg/ml.Conclusion: The non-enzymatic adduct formation between the keto group of sugar and amino group of proteins is one of the molecular basis of diabetic complications in hyperglycaemic state. Inhibition of this process will be useful in the management of diabetic complications. Lutein showed dose dependent inhibitory effect on the protein glycation.Hence, it may be used for the management of diabetic complication.

}, keywords = {Advance glycation end product, Amino-guanidine, Diabetes mellitus, Lutein}, doi = {10.5530/pj.2018.4.123}, url = {http://fulltxt.org/article/661}, author = {Karan Rajpurohit Gayathri and Roy Anitha and Thangavelu Lakshmi} }